{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genotyping&page=3",
    "query": {
      "condition": "Genotyping",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 512,
    "total_pages": 52,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genotyping&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genotyping&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T07:14:51.124Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01909804",
      "title": "Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "SOF",
          "type": "DRUG"
        },
        {
          "name": "VEL",
          "type": "DRUG"
        },
        {
          "name": "RBV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 323,
      "start_date": "2013-06",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2018-11-15",
      "last_synced_at": "2026-10-25T07:14:51.124Z",
      "location_count": 40,
      "location_summary": "Long Beach, California • Los Angeles, California • Pasadena, California + 37 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01909804"
    },
    {
      "nct_id": "NCT05368064",
      "title": "Cleidocranial Dysplasia (CCD): From Genotype to Phenotype and Considerations for Care",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cleidocranial Dysostosis"
      ],
      "interventions": [
        {
          "name": "observational",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 300,
      "start_date": "2021-10-01",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-10-22",
      "last_synced_at": "2026-10-25T07:14:51.124Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05368064"
    },
    {
      "nct_id": "NCT03636347",
      "title": "A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alpha 1-Antitrypsin Deficiency",
        "Emphysema",
        "COPD"
      ],
      "interventions": [
        {
          "name": "Placebo Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Alvelestat oral tablet - dose 1",
          "type": "DRUG"
        },
        {
          "name": "Alvelestat oral tablet - dose 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mereo BioPharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 99,
      "start_date": "2018-10-29",
      "completion_date": "2022-03-30",
      "has_results": false,
      "last_update_posted_date": "2022-04-14",
      "last_synced_at": "2026-10-25T07:14:51.124Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Sacramento, California + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Wilmington",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03636347"
    },
    {
      "nct_id": "NCT01581138",
      "title": "VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis C Virus"
      ],
      "interventions": [
        {
          "name": "VX-222",
          "type": "DRUG"
        },
        {
          "name": "telaprevir",
          "type": "DRUG"
        },
        {
          "name": "ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 64,
      "start_date": "2012-07",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2014-07-04",
      "last_synced_at": "2026-10-25T07:14:51.124Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Anaheim, California • Riverside, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01581138"
    },
    {
      "nct_id": "NCT00001469",
      "title": "Genetic Analysis of Hereditary Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Human Genome Research Institute (NHGRI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7776,
      "start_date": "1995-01-01",
      "completion_date": "2009-07-17",
      "has_results": false,
      "last_update_posted_date": "2020-03-16",
      "last_synced_at": "2026-10-25T07:14:51.124Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • Washington D.C., District of Columbia • New Orleans, Louisiana + 4 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001469"
    },
    {
      "nct_id": "NCT00927862",
      "title": "Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Thromboembolism"
      ],
      "interventions": [
        {
          "name": "IWPC adapted genotype-guided dosing algorithm for warfarin",
          "type": "GENETIC"
        },
        {
          "name": "Modified IWPC genetic-guided warfarin dosing algorithm",
          "type": "GENETIC"
        },
        {
          "name": "Standard of care treatment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "OTHER"
      ],
      "sponsor": "Intermountain Health Care, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2415,
      "start_date": "2008-08",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2012-09-25",
      "last_synced_at": "2026-10-25T07:14:51.124Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00927862"
    },
    {
      "nct_id": "NCT01984294",
      "title": "Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic HCV Infection"
      ],
      "interventions": [
        {
          "name": "LDV/SOF",
          "type": "DRUG"
        },
        {
          "name": "RBV",
          "type": "DRUG"
        },
        {
          "name": "GS-9669",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2013-10",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2018-11-19",
      "last_synced_at": "2026-10-25T07:14:51.124Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01984294"
    },
    {
      "nct_id": "NCT05630066",
      "title": "A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Angelman Syndrome"
      ],
      "interventions": [
        {
          "name": "Alogabat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 48,
      "start_date": "2023-07-27",
      "completion_date": "2025-12-02",
      "has_results": false,
      "last_update_posted_date": "2025-12-04",
      "last_synced_at": "2026-10-25T07:14:51.124Z",
      "location_count": 6,
      "location_summary": "Chicago, Illinois • Boston, Massachusetts • New York, New York + 3 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Carrboro",
          "state": "North Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05630066"
    },
    {
      "nct_id": "NCT02073656",
      "title": "Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C Virus",
        "HIV"
      ],
      "interventions": [
        {
          "name": "LDV/SOF",
          "type": "DRUG"
        },
        {
          "name": "RBV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 335,
      "start_date": "2014-02",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2018-11-16",
      "last_synced_at": "2026-10-25T07:14:51.124Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 31 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02073656"
    },
    {
      "nct_id": "NCT01813695",
      "title": "Preemptive Genotyping and Pain Management",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pain"
      ],
      "interventions": [
        {
          "name": "Preemptive genotyping in medical record",
          "type": "PROCEDURE"
        },
        {
          "name": "Genotyping not included in electronic medical record",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "6 Years to 21 Years"
      },
      "enrollment_count": 576,
      "start_date": "2013-03",
      "completion_date": "2022-12-30",
      "has_results": false,
      "last_update_posted_date": "2024-02-22",
      "last_synced_at": "2026-10-25T07:14:51.124Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01813695"
    }
  ]
}